Translational Pathology Core

项目摘要-摘要(翻译病理学核心) 翻译病理学核心的首要任务是收集与 临床信息，并分发给孢子研究人员，以促进翻译研究。《翻译》 病理学核心将设在病理学系内并由其管理，以确保 不折不扣的患者护理、有限组织资源的最佳利用以及患者的机密性。具体的 CORE的目标包括：(1)坚定不移的病人护理和适当的外科病理诊断。所有组织 将根据IRB批准的协议收集。(2)预期采购适当的大脑、乳房、 胰腺和其他未来组织，根据孢子项目的需要而定。核心将密切合作 与和加强现有的组织与分子病理学共享组织采购服务 密歇根大学罗杰尔癌症中心的资源。托马斯·佐丹诺博士是这项研究的负责人 自1996年以来一直共享资源。(3)外科手术后人体组织的病理鉴定 病理标本。Sriram Venneti博士是一位神经病理学家，也是一位有成就的胶质瘤研究者，他将回顾 所有脑组织，在胰腺癌方面具有特殊专长的胃肠道病理学家施佳琪博士将审查所有 胰腺组织和托马斯·佐丹诺博士，他是一位拥有数十年乳房经验的外科病理学家 病理学，将审查所有的乳房组织。根据需要，来自卫生部的其他专家病理学家 将招募病理学来支持核心。(4)基于组织的基因表达和生物标志物验证 研究，如免疫组织化学，根据孢子项目的需要。达菲德博士 托马斯是一位基于组织的研究专家，他将领导这些努力。总体而言， 翻译病理学核心将通过促进翻译研究来支持这些项目，并增强 其他NCI支持的网络的资源。

PROJECT SUMMARY-ABSTRACT (Translational Pathology Core) The overarching mission of the Translational Pathology Core is to collect human tissues associated with clinical information and distribute to SPORE investigators to facilitate translational research. The Translational Pathology Core will be housed and administered within the Department of Pathology to ensure uncompromised patient care, optimal use of limited tissue resources, and patient confidentiality. The specific goals of the core include: (1) Uncompromised patient care and proper surgical pathology diagnosis. All tissues will be collected under IRB-approved protocols. (2) Prospective procurement of appropriate brain, breast, pancreas and other future tissues as dictated by the needs of the SPORE projects. The core will work closely with and enhance the existing Tissue Procurement Service of the Tissue and Molecular Pathology Shared Resource of the University of Michigan Rogel Cancer Center. Dr. Thomas Giordano has been a director of this shared resource continuously since 1996. (3) Expert pathology review of human tissues from surgical pathology specimens. Dr. Sriram Venneti, a neuropathologist and accomplished glioma investigator, will review all brain tissues, Dr. Jiaqi Shi, a GI pathologist with special expertise in pancreas cancer, will review all pancreas tissues, and Dr. Thomas Giordano, a surgical pathologist with decades of experience in breast pathology, will review all breast tissues. As needed, other expert pathologists from the Department of Pathology will be recruited to support the core. (4) Tissue-based gene expression and biomarker validation studies, such as immunohistochemistry, as indicated by the needs of the SPORE projects. Dr. Dafydd Thomas, an expert in tissue-based investigation, will lead these efforts. Collectively, the services of the Translational Pathology Core will support the projects by facilitating translational research and also enhance the resources of other NCI-supported networks.